University of Southern California

Biovinc LLC

University of California

Isis Innovation Limited

The Procter Gamble Company

Mark Walden Lundy

Frank Hallock Ebetino

Charles E McKenna

Shuting Sun

Keivan Sadrerafi

Adam W Mazur

Ichiro Nishimura

Akishige Hokugo

Eric T Richard

Parish Sedghizadeh

Philip T Cherian

Robert Graham Russell

Mitchell Anthony DeLong

James Richard Hartke

Robert Graham Goodwin Russell

Described herein are bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein are methods of making and methods of using the bisphosphonate quinolone compounds, conjugates and pharmaceutical formulations thereof.

Bisphosphonate quinolone conjugates and uses thereof

Disclosed herein are methods and compositions for removing or displacing bisphosphonates in skeletal tissue.

Skeletal removal of bisphosphonates

Novel imidazo[1,2-&#x3b1;]pyridinyl bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.

Imidazo[1,2-a] pyridinyl bisphosphonates

Novel 5-azaindole bisphosphonate compounds are disclosed, as well as methods of preparing the compounds, pharmaceutical compositions including the compounds, and administration of the compounds in methods of treating abnormal calcium and phosphate metabolism, including bone and joint diseases and other disorders.

5-azaindole bisphosphonates

The present invention relates to novel methods of increasing bone volume comprising the administration of a non-naturally-occurring selective FP agonist to a subject in need of such treatment. This invention further relates to a method of treating or preventing bone disorders comprising the administration of a non-naturally-occurring selective FP agonist to a subject in need of such treatment.

Method of increasing bone volume using non-naturally-occurring FP

Growing community of inventors

Cincinnati, OH, United States of America

Mark Walden Lundy